Jump to main content
Jump to site search

MedChemComm

Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry

Research Article

Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile

*
Corresponding authors
a
Pfizer Inc. Medicine Design, 610 Main Street, Cambridge, 02155 USA
E-mail: Kim.Huard@Pfizer.com
b
Pfizer Inc. Medicine Design, Eastern Point Road, Groton, 06340 USA
E-mail: Daniel.W.Kung@pfizer.com
c
Pfizer Inc. Drug Safety Research and Development, Eastern Point Road, Groton, 06340 USA
d
Pfizer Inc. Cardiovascular and Metabolic Disease Research Unit, 610 Main Street, Cambridge, 02155 USA
Med. Chem. Commun., 2017, Advance Article

DOI: 10.1039/C6MD00564K
Received 12 Oct 2016, Accepted 08 Nov 2016
First published online 22 Nov 2016

This article is part of themed collection: New Talent: Americas
Please wait while Download options loads
 
 
This article has not yet been cited.

Supplementary Info